Search Results
Mar 17, 2026, 07:05 ET RealAcoustix Officially Launches GuD™ Panel Acoustic Diffuser Line
GuD PXR – The latest evolution of Asymmetrical Cellular Acoustic Diffuser (ACAD) technology, combining distinctive aesthetics with robust diffusion in ceiling applications.For a detailed comparison of the GuD line,
More news about: RealAcoustix
Mar 16, 2026, 07:00 ET Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729-735. doi:10.1016/j.jaad.2013.07.023Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242-248. doi:10.1016/j.jaad.2015.05.00©
More news about: Sun Pharmaceutical Industries Inc., USA (Sun Pharma)
Mar 16, 2026, 06:45 ET Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis
moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11. doi:10.1016/j.jaad.2018.01.017
More news about: Eli Lilly and Company
Feb 26, 2026, 06:30 ET Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
Kobilka BK, & Sloop KW, Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967,
More news about: Eli Lilly and Company
Feb 25, 2026, 11:56 ET Verão fitness: exercícios físicos podem piorar a flacidez da pele; entenda motivos e como tratar
2013;5(4):345-50.5. Morgan P, et al. Poster presented at IMCAS World Congress, 26-28 January 2023, Paris, France.6. Narins RS, et al. J Am Acad Dermatol. 2010 Mar;62(3):448-62. 7. Bonhert K, et al. Dermatol Surg. Jan 2019. 45; 718-24 8. Waibel J, et al. Poster
More news about: Galderma
Feb 20, 2026, 12:13 ET O ano começou de verdade! Conheça tratamentos que vão cuidar da sua pele em 2026
2013;5(4):345-50. 5. Morgan P, et al. Poster presented at IMCAS World Congress, 26-28 January 2023, Paris, France. 6. Narins RS, et al. J Am Acad Dermatol. 2010 Mar;62(3):448-62. 7. Bonhert K, et al. Dermatol Surg. Jan 2019. 45; 718-24 8. Waibel J, et al. Poster
More news about: Galderma
Jan 30, 2026, 13:40 ET Galderma promove treinamentos e reforça compromisso com a educação continuada em estética injetável durante o CIOSP
7. Morgan P et al. Poster presented at IMCAS World Congress, 26-28 January 2023, Paris, France. 8. Narins RS et al. J Am Acad Dermatol. 2010 Mar;62(3):448-62. 9. Bonhert K et al. Dermatol Surg. Jan 2019. 45; 718-24 10. Waibel J et al. Poster
More news about: Galderma
Jan 19, 2026, 16:11 ET Ano novo, pele nova: quais tratamentos você deve investir agora para colher resultados ao longo do ano
2013;5(4):345-50. 5. Morgan P, et al. Poster presented at IMCAS World Congress, 26-28 January 2023, Paris, France. 6. Narins RS, et al. J Am Acad Dermatol. 2010 Mar;62(3):448-62. 7. Bonhert K, et al. Dermatol Surg. Jan 2019. 45; 718-24 8. Waibel J, et al. Poster
More news about: Galderma
Dec 18, 2025, 06:45 ET Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
Kobilka, & K.W. Sloop, Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967,
More news about: Eli Lilly and Company
Dec 17, 2025, 14:15 ET O segredo da musa! Sabrina Sato revela a sua rotina de cuidados com a pele para a temporada de verão e Carnaval
study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010 Mar;62(3):448-62. 5. Goldberg D, Guana A, Volk A, Daro-Kaftan E. Single-arm study for the characterization of human tissue
More news about: Galderma
Dec 04, 2025, 10:00 ET UAG lanza programas 3+1 de doble titulación con Arizona State University (ASU)
https://mma.prnewswire.com/media/2837839/Vicerrector_Acad_micao_y_de_Ciencias_de_la_Salud_de_la_U_AG__Dr__Alfonso_Peterse.jpg
More news about: Universidad Autónoma de Guadalajara
Dec 03, 2025, 16:56 ET Tendências para 2026: esses são os procedimentos estéticos que estarão em alta para o ano que vem
2013;5(4):345-50.5. Morgan P, et al. Poster presented at IMCAS World Congress, 26-28 January 2023, Paris, France.6. Narins RS, et al. J Am Acad Dermatol. 2010 Mar;62(3):448-62.7. Bonhert K, et al. Dermatol Surg. Jan 2019. 45; 718-248. Waibel J, et al. Poster presented at the
More news about: Galderma
Nov 21, 2025, 09:47 ET Cuidados combinados: como o skincare diário e os procedimentos estéticos se complementam para melhorar a qualidade da pele
study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010 Mar;62(3):448-62.6. Weiss RA et al. Dermatol Surg. 2016 Jun;42(6):699-7099. Bonhert K, et al. Randomized, Controlled, Multicentered,
More news about: Galderma
Nov 17, 2025, 11:49 ET ANS abre consulta pública para decidir sobre a inclusão de novo medicamento para dermatite atópica
[1] Ring J, Zink A, Arents BWM, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol. Jul 2019;33(7):1331-1340. doi:10.1111/jdv.15634 [2] Silverberg JI, Gelfand JM,
More news about: Eli Lilly do Brasil
Nov 07, 2025, 16:07 ET Conheça os procedimentos que são eficazes para melhorar o rosto flácido após perda de peso induzida por medicamentos
study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010 Mar;62(3):448-62.6. Weiss RA et al. Dermatol Surg. 2016 Jun;42(6):699-709
More news about: Galderma
Nov 07, 2025, 11:00 ET "The Experience By UAG": espacio único para impulsar la innovación
https://mma.prnewswire.com/media/2816187/The_Experience_es_el_magno_acad_mico_del_a_o_en_la_U_AG.jpg
More news about: Universidad Autónoma de Guadalajara
Nov 06, 2025, 13:54 ET Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
Kobilka, & K.W. Sloop, Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967,
More news about: Eli Lilly and Company
Nov 03, 2025, 08:00 ET Orforgliprona, GLP-1 oral da Lilly, demonstra controle glicêmico superior em dois estudos bem-sucedidos de Fase 3, reconfirmando seu potencial como opção de tratamento do diabetes tipo 2
Kawabe, B.K. Kobilka, & K.W. Sloop, Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist, Proc. Natl. Acad. Sci. U.S.A. 117 (47) 29959-29967, https://doi.org/10.1073/pnas.2014879117(2020).
More news about: Eli Lilly do Brasil
Oct 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Oct 27, 2025, 17:02 ET Autocuidado masculino: homens recorrem a procedimentos estéticos para realçar a beleza e cuidar da pele
safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010 Mar;62(3):448-62.6. Weiss RA et al. Dermatol Surg. 2016 Jun;42(6):699-709 27. Machado Filho CDS et
More news about: Galderma
Oct 25, 2025, 11:00 ET BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729-735. Mease PJ, Armstrong A. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of
More news about: UCB
Oct 24, 2025, 12:14 ET Procedimentos estéticos injetáveis: quando é o momento certo para começar?
safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010 Mar;62(3):448-62. Sobre a Galderma A
More news about: Galderma
Oct 24, 2025, 08:00 ET Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
3 Goldblum O, et al. Validation of the physician's global assessment of psoriasis of the hands and/or feet as a clinical endpoint. J Am Acad Dermatol. 2013:68(4)Supplement1:AB218.
More news about: Johnson & Johnson
Oct 24, 2025, 06:45 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11. doi:10.1016/j.jaad.2018.01.017. Okragly A, et al. Binding, Neutralization and Internalization
More news about: Eli Lilly and Company
Oct 23, 2025, 11:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP